ºñÀÓ»ó °øµ¿¿¬±¸

Nonclinical Study

¾È±¹¾àÇ°ÀÇ ±â¼ú·Î »î¿¡´Â °Ç°­À»
¹Ì·¡¿¡ Èñ¸ÁÀ» ÀüÇÏ°Ú½À´Ï´Ù.

ºñÀÓ»ó À¯È¿¼º Æò°¡

  • In vitro/In vivo ¾àÈ¿ Æò°¡: ÀÇ·ÚÀÚÀÇ needs¸¦ ÃæÁ·ÇÏ´Â À¯È¿¼º Æò°¡ ¾÷¹«¸¦ ¼öÇà °¡´É
  • ¹ÙÀÌ¿ÀÀǾàÇ° Ÿ°Ù¿¡ ÃÖÀûÈ­µÈ Æò°¡ ½Ã½ºÅÛ º¸À¯
  • À¯È¿¼º Æò°¡¸ðµ¨ °³¹ß: Àü¹®ÀηÂÀ¸·Î ±¸¼ºµÈ ¿¬±¸Áø°ú ½ÇÇè µðÀÚÀÎÀ» ¼³°èÇÏ°í °³¹ß
  • ÷´Ü Àåºñ È°¿ë ±â¼ú ¼­ºñ½º Áö¿ø: IVIS, FACS µîÀ» È°¿ëÇÑ Bio-distribution ¹× TIL analysis ºÐ¼® °¡´É
1. Cell line derived tumor model (Syngeneic / Xenograft)
¾ÏÁ¾ Æò°¡ ¸ðµ¨ Æò°¡Ç׸ñ
Colon MC38, CT26 Tumor growth,
Orthotopic (MFD),
Kaplan-Meier survival,
Metastasis,
Re-challenge,
TIL-analysis,
ÇùÀÇ ÈÄ ÁøÇà
Breast 4T1
MDA-MB-231
Melanoma B16F10
Lung A549
Lymphoma E.G7
Etc ±âŸ ¼¼Æ÷ÁÖ ¹®ÀÇ °¡´É
2. PBMC Humanized immnune system (HIS) model
3. Bioluminesence in vivo imaging

4. In vitro À¯È¿¼º Æò°¡

T cell activation, MLR assay, T cell restoration, Tumor lysis & cytokine release, ADCC/CDC/ADCP